EUVIMEDOpdag EUVIMED
Multizentrische StudieBeobachtungsstudieOpen access · CC BY-NC-ND 4.0

RANKL Inhibition and the Risk of Ocular Hypertension and Primary Open-Angle Glaucoma

Chien-Yun Tsai, Chien-Hsiang Weng, Yi Jing Sheen, Jun-Peng Chen, Hsian-Min Chen, Ching-Yao Tsai, I-Jong Wang, Chien-Chih Chou

Investigative Ophthalmology & Visual Science · 2026

DOI: 10.1167/iovs.67.6.8 ↗

At a glance

Multizentrische Studie in Investigative Ophthalmology & Visual Science, 2026. Written by Chien-Yun Tsai and 7 co-authors. Institution: School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Major MEDLINE topics: Bone Density Conservation Agents, Denosumab, Glaucoma, Open-Angle, Ocular Hypertension. 47 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

To investigate whether the receptor activator of NF-κB ligand (RANKL) inhibitor denosumab is associated with a lower risk of developing ocular hypertension (OHT) and primary open-angle glaucoma (POAG) compared with bisphosphonate therapy in patients with osteoporosis.

Methods

We conducted a multinational, retrospective cohort study using the TriNetX network from 2013 to 2023. Adults 40 years or older with osteoporosis who received denosumab were propensity score matched 1:1 to those receiving bisphosphonates. The primary outcomes were incident OHT and POAG within 5 years. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs). Sensitivity analyses included extending follow-up to 10 years, requiring an ophthalmology visit to strengthen diagnostic validity, and adjusting for additional cardiometabolic medications. Subgroup analyses further stratified participants by age, sex, race, diabetes, and corticosteroid use.

Results

After 1:1 propensity score matching, a total of 94,624 patients (47,312 in each cohort) were included in each cohort. Compared with bisphosphonate therapy, denosumab use was associated with a significantly lower risk of developing OHT (HR = 0.72; 95% CI, 0.59-0.88) and POAG (HR = 0.63; 95% CI, 0.53-0.75). These associations remained robust across all sensitivity analyses and were consistently observed across major patient subgroups.

Conclusions

Among adults with osteoporosis, denosumab use was associated with significantly lower risks of OHT and POAG compared with bisphosphonate therapy. These findings highlight the potential ocular relevance of RANKL inhibition and support further investigation into its clinical implications through prospective studies.

Subjects

MeSH terms (MEDLINE)

Bone Density Conservation AgentsDenosumabGlaucoma, Open-AngleOcular HypertensionOsteoporosisRANK LigandAdultAgedFemaleHumansMaleMiddle AgedDiphosphonatesIncidenceIntraocular PressurePropensity ScoreRetrospective StudiesRisk Factors

Substances

Bone Density Conservation AgentsDenosumabDiphosphonatesRANK LigandTNFSF11 protein, human

Authors and institutions

  • School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Ophthalmology, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Family Medicine, Brown University Warren Alpert Medical School, Providence, Rhode Island, United States.
  • Brown University Health, Providence, Rhode Island, United States.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.

Cite

APA

Tsai, C. Y., Weng, C. H., Sheen, Y. J., Chen, J. P., Chen, H. M., Tsai, C. Y., Wang, I. J., & Chou, C. C. (2026). RANKL Inhibition and the Risk of Ocular Hypertension and Primary Open-Angle Glaucoma. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.6.8

Vancouver

Tsai CY, Weng CH, Sheen YJ, Chen JP, Chen HM, Tsai CY, et al. RANKL Inhibition and the Risk of Ocular Hypertension and Primary Open-Angle Glaucoma. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.6.8

BibTeX
@article{Tsai2026,
  author = {Tsai, Chien-Yun and Weng, Chien-Hsiang and Sheen, Yi Jing and Chen, Jun-Peng and Chen, Hsian-Min and Tsai, Ching-Yao and Wang, I-Jong and Chou, Chien-Chih},
  title = {RANKL Inhibition and the Risk of Ocular Hypertension and Primary Open-Angle Glaucoma},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2026},
  doi = {10.1167/iovs.67.6.8}
}
Start for free →